Lilly’s $7.8 Billion Bet Takes It Beyond Obesity Into Sleep
Scooping up Centessa gives Lilly a foothold in narcolepsy and a promising new class of wakefulness drugs. www.bloomberg.com #Lillys #Billion #Bet…
Tag: obesity
Innovent Biologics Bullish on China Obesity Drug Outlook
Innovent Biologics has reported its first profit even as competition from weight-loss generics looms. Speaking exclusively to Bloomberg’s “The China…
Innovent Shares Jump on First Profit, Obesity Drug Momentum
Innovent Biologics Inc. shares saw their biggest gains in nearly five months, after the Chinese drugmaker posted its first annual…
Pfizer Secures China Rights to Obesity Drug in $495 Million Deal
Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the fast-growing weight…
Eli Lilly’s lead in the obesity race gets wider after win against Novo
In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair of headlines…
What signal Lilly sends by stockpiling GLP-1 obesity pills ahead of FDA approval
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time…
Novo Nordisk faces defining year in the obesity drug market
Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight loss drugs at the…
FDA says Novo Nordisk’s obesity pill TV ad includes misleading claims
The Food and Drug Administration said Novo Nordisk‘s TV advertisement for its newly launched Wegovy pill for obesity included “false…
Novo Nordisk sues Hims & Hers over compounded obesity drugs
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4,…
Pfizer execs talk Metsera obesity drug
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York…